Brokerages Set Akero Therapeutics, Inc. (NASDAQ:AKRO) Price Target at $46.83

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) have been assigned an average rating of “Moderate Buy” from the eight analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $46.83.

A number of brokerages have commented on AKRO. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Akero Therapeutics in a research note on Thursday, January 16th. Citigroup assumed coverage on Akero Therapeutics in a research note on Monday, November 18th. They issued a “buy” rating and a $65.00 price objective on the stock.

Insider Activity at Akero Therapeutics

In other Akero Therapeutics news, insider Catriona Yale sold 4,515 shares of Akero Therapeutics stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $32.53, for a total value of $146,872.95. Following the transaction, the insider now owns 74,158 shares in the company, valued at $2,412,359.74. The trade was a 5.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Andrew Cheng sold 108,366 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $31.73, for a total transaction of $3,438,453.18. Following the completion of the transaction, the chief executive officer now owns 605,417 shares of the company’s stock, valued at $19,209,881.41. This represents a 15.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 262,135 shares of company stock valued at $8,223,000 over the last ninety days. 7.94% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. American Century Companies Inc. acquired a new stake in Akero Therapeutics in the second quarter valued at approximately $347,000. Renaissance Technologies LLC purchased a new stake in shares of Akero Therapeutics during the 2nd quarter valued at $565,000. Ensign Peak Advisors Inc boosted its position in shares of Akero Therapeutics by 2.1% in the 2nd quarter. Ensign Peak Advisors Inc now owns 237,494 shares of the company’s stock worth $5,572,000 after purchasing an additional 4,950 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Akero Therapeutics by 26.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 107,172 shares of the company’s stock worth $2,514,000 after buying an additional 22,195 shares during the last quarter. Finally, Long Focus Capital Management LLC increased its position in Akero Therapeutics by 119.0% during the 2nd quarter. Long Focus Capital Management LLC now owns 719,604 shares of the company’s stock valued at $16,882,000 after buying an additional 391,000 shares in the last quarter.

Akero Therapeutics Trading Up 0.1 %

Shares of NASDAQ AKRO opened at $26.18 on Monday. Akero Therapeutics has a fifty-two week low of $15.32 and a fifty-two week high of $37.00. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The company has a market cap of $1.83 billion, a price-to-earnings ratio of -6.98 and a beta of -0.19. The business’s 50 day moving average price is $28.47 and its 200-day moving average price is $28.11.

Akero Therapeutics (NASDAQ:AKRO) last released its earnings results on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.15). On average, sell-side analysts expect that Akero Therapeutics will post -3.96 earnings per share for the current year.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.